64 results about "Autologous cell" patented technology

Disclosed are methods of isolating T cells having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising: inducing autologous APCs of the patient to present the mutated p53 amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated p53 amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.

Provided herein are tumor-antigen VGLL1 specific T cell receptors. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer. Methods for expanding a population of T cells that target VGLL1 are also provided.

The present invention relates to a device for a scalable biomanufacturing platform for the production of modified cells such as CAR-modified T-cells while eliminating on-target / off-tumor toxicity and decreasing the current production cost by 500 times (per treatment), and to attendant methods. The includes a first chamber for proliferating a population of cells and a second chamber for modifying the cells to express a desired T-cell receptor antigen.

The invention discloses an autologous NK cell in-vitro culture method for improving purity and amplification multiple, and belongs to the technical field of biology. In order to overcome the defect that in-vitro large-scale amplification and activation of autologous NK cells of unhealthy people (solid tumor patients) are difficult, the autologous NK cells are obtained from peripheral blood of the patients, autologous CD3 + cells are used as trophoblast layers, the autologous NK cells of the patients are efficiently amplified in vitro, the cell purity reaches 99% or above, biosafety risks do not exist, and the autologous NK cells of the patients can be efficiently amplified in vitro. Moreover, an efficient anti-tumor effect is also shown in vivo, the bottleneck of in-vitro amplification of autologous NK cells of a patient is overcome, and a new direction is provided for cellular immunotherapy of the patient.

The invention discloses a decellularized artificial lymph drainage tube and a preparation method and application thereof, and the preparation method of the decellularized artificial lymph drainage tube comprises the following steps: taking an animal blood vessel as a raw material, and performing decellularization treatment, cleaning treatment, enhancement treatment, hole forming treatment and drying treatment on the raw material. The decellularized artificial lymph drainage tube prepared by the preparation method can solve the problems of long consumed time and difficult operation of the existing lymphatic vessel-vein anastomosis operation, can drain the lymph at the swelling part of a patient to the vein system in time after implantation, and can quickly relieve the swelling symptom. The decellularized artificial lymph drainage tube supports ingrowth, migration and proliferation of autologous cells and is good in biocompatibility, the degradation time can be adjusted to be matched with the reconstruction time of an autologous lymphatic reflux system, and long-term patency is guaranteed.

The present invention relates to the field of T cells and provides methods of producing autologous T cells and compositions thereof for the treatment of B-cell malignancies and other cancers. A method of making T cells expressing a cell surface receptor that recognizes a specific antigen moiety on the surface of a target cell, the method comprising enriching a population of lymphocytes; stimulating the population of lymphocytes with one or more T cell stimulators to produce a population of activated T cells, the stimulation being performed in a closed system using a serum-free culture medium; transduction of the activated population of T cells with a viral vector comprising a nucleic acid molecule encoding a cell surface receptor, producing a transduction population of T cells using single cycle transduction, the transduction being performed in a closed system using a serum-free culture medium; the transduced population of T cells is expanded for a predetermined time resulting in an engineered population of T cells, the expansion being performed in a closed system using a serum-free culture medium. The methods and processes described herein can be completed in significantly shorter time.

The present invention relates to a method for enhancing production of autologous genetically engineered T cells for use in cell therapy applications.

In the field of gene therapy, a major hurdle is the design and identification of constructs and gene therapy vectors providing therapeutic effects while displaying satisfactory safety profiles. In the treatment of Diamond-Blackfan Anemia (DBA), therapies alleviating several crucial anemia symptoms, such as blood or bone marrow cellularity, hemoglobin levels, erythrocytes levels, or platelet levels, while showing satisfactory safety profiles remain a challenge. The present invention provides constructs encoding ribosomal protein genes involved in DBA, such as genes encoding RPS19, RPS17, RPS24, RPS10, RPL35a, RPL11, RPS26, and RPL5, vectors, methods, cells, and medical uses thereof, addressing these challenges and finding particular applications in the field of autologous cell therapy treatment of DBA. Further, the present invention provides a non-genotoxic conditioning protocol for preparing a subject prior to cell therapy treatment for DBA using construct of the present invention.

CD38 is also expressed in a variety of hematological malignancies, including multiple myeloma. In the present invention, the inventors obtained a new antibody against CD38 that can be used to produce bispecific antibodies and CAR T cell populations. In particular, the inventors reported the development of Bi38-3, a new bispecific T cell engager that targets CD38 on MM cells and forms cytotoxic T cells through CD3ε. Bi38-3 lacks the Fc region of natural mAbs, which contributes to the resistance process, but triggers T cell proliferation, cytokine release, and lysis of CD38-positive MM cells in vitro. Similarly, Bi38-3 induces autologous T cells to eliminate tumor plasma cells isolated from MM patients at diagnosis and relapse. The cytotoxicity triggered by Bi38-3 is limited to cells expressing high levels of CD38 and maintains the integrity of T, B, and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in the MM1.S xenograft mouse model of human MM. In summary, the results show that the antibody of the present invention is an effective agent for specifically eliminating CD38-positive malignant cells without significantly affecting CD38-low-expressing cells, and is a promising new immunotherapy tool for treating malignant blood diseases, especially multiple myeloma.

The invention provides a pharmaceutical composition for treating triple negative breast cancer and application thereof, the pharmaceutical composition comprises beta-nicotinamide mononucleotide and an anti-PD-1 antibody, the administration mode of the beta-nicotinamide mononucleotide is oral administration or treatment of autologous CD8 + T cells of a patient by using the beta-nicotinamide mononucleotide, and the treated CD8 + T cells are transfused back into the body of the patient. In-vitro experiments and animal experiments show that the beta-nicotinamide mononucleotide and the anti-PD-1 antibody are combined for use, the activity of tumor cells is remarkably reduced, the killing capacity of CD8 + T cells is remarkably improved, the beta-nicotinamide mononucleotide can improve the effect of immunotherapy of the anti-PD-1 antibody on triple negative breast cancer, and the beta-nicotinamide mononucleotide and the anti-PD-1 antibody have a remarkable synergistic effect. The beta-nicotinamide mononucleotide and the anti-PD-1 antibody are combined for use, so that benefits of more patients are achieved, the treatment effect is improved, meanwhile, the market potential of related drugs is widened, the life quality of the patients is expected to be improved, and important innovation and commercial opportunities are brought to the medical field.

To provide methods for generating midbrain dopamine (mDA) neural progenitor cells useful for autologous cell therapy in Parkinson's disease, compositions comprising the cells, and methods of use thereof.SOLUTION: Provided is a method of producing a population of mesencephalic dopaminergic progenitor cells (mDAP), comprising the steps of providing a population of induced pluripotent stem cells (iPSC), preferably human iPSC, seeding said population of cells in discrete regions within a biological matrix hydrogel support at a density of about 5,000 to 20,000, preferably about 10,000 cells per region with a distance between said regions sufficient to maintain separation between said regions, and maintaining said cells under conditions sufficient for said iPSC to differentiate into mDAP.SELECTED DRAWING: None

The invention relates to the technical field of stem cell biological medicine, and discloses an allogenic mesenchymal stem cell preparation for treating liver injury as well as a preparation method and application thereof, and an exogenous CD47 gene is introduced into mesenchymal stem cells. The cell line stably carries the CD47 gene, the immunological rejection resistance of the mesenchymal stem cells can be remarkably improved, the residence capacity of the mesenchymal stem cells can be remarkably enhanced, and a new solution is provided for a host to eliminate the immunological rejection problem of the mesenchymal stem cells. The mesenchymal stem cells are derived from healthy donors, the source is wide, the multiplication capacity is high, the mesenchymal stem cells still have the capacity of self-renewal and multidirectional differentiation after multiple passages, the technology is expected to solve the problem that stem cell transplantation is limited by the number of autologous cells and immunological rejection, and the mesenchymal stem cells have great application prospects.

The present disclosure provides an autologous cell therapy for treating a cancer. Transarterial tirapazamine embolization (TATE) therapy induces tumor necrosis, which, in combination with anti-PD-1 therapy, enhances the efficacy of anti-PD-1 through TATE-induced expansion of anti-tumor T cells activated by the anti-PD-1 antibody. PBMCs collected from TATE and PD-1 -treated patients for RNA and DNA extraction and next generation sequencing (NGS) analysis of complementarity region-3 of the TCR from T cell populations in the PBMCs show that clonal expansion of anti-tumor specific T cell receptors (TCRs) occurs. Expansion of the PBMC population for administration to a cancer patient preferentially expands the population of effector T cells targeting the tumor cells without a need for genetic manipulation.

The invention discloses a cell population as well as a preparation method and application thereof, and belongs to the technical field of biology. The cell population comprises engineered immune cells, the engineered immune cells comprise an exogenous nucleic acid, the insertion of the exogenous nucleic acid into a B2M gene fragment region causes the B2M gene to be disrupted, and the exogenous nucleic acid comprises a nucleic acid encoding a chimeric antigen receptor. The cell population destroys B2M by knocking nucleic acid encoding a chimeric antigen receptor (CAR) into a B2M locus, can be used for preparing a universal cell therapy product, and overcomes the problems that autologous T cell therapy is limited by the number and quality of T cells of a patient, and the preparation period is long.

The present disclosure relates to the technical field of biomaterials, and provides a catechol-functionalized gelatin microsphere and a use thereof in preparation of a product for inhibiting formation of subcutaneous fluid accumulation and promoting tissue repair. The catechol-functionalized gelatin microsphere designed and prepared in the present disclosure not only has wet tissue adhesion capability, but also has good liquid absorption performance and biodegradability. The results of cell experiments show that abundant interfaces of catechol-functionalized gelatin microspheres can promote cell adhesion and proliferation, and the loose structure of the microspheres can also promote cell migration. The results of chest wall defect repair experiments of New Zealand white rabbits show that the catechol-functionalized gelatin microspheres can not only inhibit formation of subcutaneous fluid accumulation, but also recruit autologous cells in situ and promote proliferation thereof and secretion of extracellular matrix (such as collagen). These results indicate that the catechol-functionalized gelatin microsphere material has clinical application potential of inhibiting the formation of subcutaneous fluid accumulation, and promoting subcutaneous tissue regeneration and wound healing.

Disclosed herein are multi-antigenic autologous, cell-based SARS-CoV-2 vaccines comprising autologous antigen presenting cells (APCs) displaying at least two different SARS-CoV-2 antigens. These vaccines can be used to prevent SARS-CoV-2 infection or COVID-19. Further disclosed are methods for producing and using the vaccines.

The invention relates to the technical field of immune cells, and discloses a rat NK cell separation and multiplication culture method which comprises the following steps: screening rat PBMC cells in a CD161 + positive screening mode to obtain rat NK cells; the rat NK cells and the rat PBMC cells are mixed and co-cultured, and the working concentration of the interleukin growth factor is adjusted in stages in the culture process. In the scheme of the application, the rat NK cells obtained by separation and amplification in the peripheral blood of the rat have the characteristics of large quantity, strong functional activity, no infectious pathogen pollution and the like, and can be used as an important source of non-autologous NK cells; abundant cell sources can be provided for clinically using non-autologous NK cells to treat diseases such as malignant tumors and virus infection. Meanwhile, efficient amplification of the rat NK cells can be realized, and the obtained rat NK cells have the characteristics of high purity and high activity.

Methods and compositions of matter for the treatment of multiple organ dysfunction syndrome using products derived from autologous pluripotent derived stem cells. Autologous pluripotent stem cells can be induced to differentiate into therapeutic cell populations including mesenchymal stem cell and regulatory T cell populations in the presence of a decellularized matrix. Said cells can be transfected with therapeutic genes to enhance function and activity upon administration to a subject. Combinations of autologous cell types can be utilized. In such combinations, the cell populations are conditioned to regulate disease and modulate immune responses for the treatment of multiorgan failure.

The present invention relates to the field of T cells and provides methods of producing autologous T cells and compositions thereof for the treatment of B-cell malignancies and other cancers. A method of making T cells expressing a cell surface receptor that recognizes a specific antigen moiety on the surface of a target cell, the method comprising enriching a population of lymphocytes; stimulating the population of lymphocytes with one or more T cell stimulators to produce a population of activated T cells, the stimulation being performed in a closed system using a serum-free culture medium; transduction of the activated population of T cells with a viral vector comprising a nucleic acid molecule encoding a cell surface receptor, producing a transduction population of T cells using single cycle transduction, the transduction being performed in a closed system using a serum-free culture medium; the transduced population of T cells is expanded for a predetermined time resulting in an engineered population of T cells, the expansion being performed in a closed system using a serum-free culture medium. The methods and processes described herein can be completed in significantly shorter time.

Embodiments relate to a living tissue graft derived from autologous cells used to provide support or to strengthen / reinforce compromised tissue. The living tissue graft comprises both cells and extracellular matrix (ECM) and overcomes problems related to foreign body responses to synthetic materials and rejection reactions to allograft tissue.

The invention provides a driver fatigue early warning method, device and equipment and a storage medium, and relates to the technical field of safety monitoring. The method comprises the following steps: acquiring hiPSC derived myocardial cells; placing the cells in vitro for culturing; detecting cell physiological indexes and calculating an ischemic tolerance score; determining a driving safety threshold value of the target driver; collecting current driving data; and when the current driving data reaches or exceeds a driving safety threshold value, an early warning signal is triggered. According to the method, by detecting the tolerance of the autologous cells of the driver in the simulated anoxic environment, accurate evaluation based on individual biological characteristics is achieved, and the defect that a general standard cannot adapt to individual differences is overcome. By converting the tolerance limit of the cellular level into the personalized driving safety threshold value and performing real-time monitoring, predictive alarm can be performed before physiological collapse, and the active prevention capability of sudden diseases caused by driving fatigue is remarkably improved.

The present invention belongs to the technical field of cellular anti-aging, and specifically relates to a small-molecule compound composition capable of reversing the senescence of an adult stem cell and restoring the regeneration activity thereof, and a method for reversing cellular senescence by means of using a chemical small-molecule composition and the use thereof. The composition capable of reversing cellular senescence comprises a WNT / β-catenin agonist, a TGF-β receptor inhibitor, an RAR agonist, a Smoothened receptor agonist, a multi-target inhibitor of the VEGFR and PDGFR families, a histone methyltransferase inhibitor, and a JAK1 / 2 inhibitor. The composition effectively solves the problem of the weak proliferation and regeneration potential of senescent adult stem cells, effectively reverses the senescence of the adult stem cells and maintains the intrinsic biological characteristics of the cells, and can thus improve and enhance the efficacy of clinical autologous cell transplantation therapy and cell derivative therapy.

The invention relates to the technical field of adoptive cellular immunotherapy, in particular to application of Tim-3 and an autologous RAK cell culture method. The invention provides application of Tim-3 as an inhibition target to improvement of the anti-tumor effect of RAK cells, and provides an autologous RAK cell culture method and a tumor treatment method. According to the invention, by closing the Tim-3 antigen on the autologous RAK cell, the immunosuppression effect of Tim-3 and the ligand thereof is relieved, so that the killing ability of the autologous RAK cell to the positive tumor of the Tim-3 ligand is enhanced.

This invention relates to methods for treatment of diseases of aging including immunosenescence, immune dysfunction, inflammation and impairment of early lymphoid lineage differentiation. The invention more specifically relates to the use of granulocyte colony stimulating factors to assist in stem cell mobilization, optionally in combination with the application of a method of delivering precise magnetic field patterns which agree with the body's own natural magnetic field patterns, and further in combination with re-infusion of previously collected autologous cells and / or plasma, optionally including allogeneic (healthy donor) cells and blood plasma.

The present disclosure provides a medical procedure kit for ameliorating tissue damage in a patient, the kit comprising a container enclosing a receptacle, an extractor for extracting biological material including autologous cells from the patient, a strainer for straining autologous cells from the biological material and an implantable support having a surface onto which the autologous cells can adhere, the implantable support configured to be received by the receptacle. Also disclosed are related methods of manufacturing a medical material and using the medical procedure kit.

A method of removing senescent cells from donor tissues or cells, organs, or autologous cells or tissues forms a tissue graft. The method comprises adding at least one senolytic therapy to the tissue or cells during processing or prior to storage. The senolytic therapy preferably involves any strategy to reduce senescent cells, reduce senescence phenotype, reduce factors that can cause senescent cells, target known senescence signaling (e.g. inhibitors or RNA therapeutics). The viable tissue graft comprises live tissue with enhanced biological properties. The amount of senescent cells in the graft is reduced by at least 15% as compared to an amount of senescent cells present in normal tissue. The amount of senescence-associated secretory phenotype SASPs in the graft is reduced by at least 10% as compared to an amount of senescence-associated secretory phenotype SASPs present in normal cells.

The application provides a preparation method of autologous cell source nanovesicle loaded miRNA in intervertebral disc degeneration, and steps include: (1) adding miRNA mimics into PBS resuspension of nucleus pulposus cells; (2) using polycarbonate membrane with gradient pore size reduction and NV preparation instrument to extrude the nucleus pulposus cells, and obtaining autologous cell source NV loaded miRNA after sterilization and centrifugation; the autologous cell source nanovesicle loaded miRNA is used in preparation of drugs and complex drugs for treating intervertebral disc degeneration. The application provides a method of autologous cell source nanovesicle loaded miRNA, stress response key miRNA in intervertebral disc degeneration and biological functions thereof are recognized, and autologous nucleus pulposus cell source NV is used to load the stress response key miRNA, effective delivery of miRNA in intervertebral disc is realized, and finally the function of delaying intervertebral disc degeneration under abnormal stress load is played.

Methods for generating midbrain dopamine (mDA) neural progenitor cells useful for autologous cell therapy in Parkinson's disease, compositions comprising the cells, and methods of use thereof are provided.

Epigenetic modifications play an important role in regulating cell-specific expression patterns. Different DNA methylation signatures, for example, can be found in different tissues and even between different cell types within a particular tissue. In work leading to the present invention, the inventors found that these methylation signatures can be used to identify cfDNA tissue of origin. Moreover, these novel methylation markers can be used to detect cell, tissue or organ damage, including autologous cell, tissue or organ damage.

Compositions and methods for upregulating L1 RNA activity in a subject in need thereof are provided. The compositions include nucleic acids encoding L1 RNA or the L1 RNA, alone, or contained in an expression vector and / or further contained within osteogenic progenitor cells, for example, mesenchymal stem cells, genetically engineering to express L1 RNA. In this aspect, the compositions are used to increase L1 RNA levels for example, L1 RNA copy number in subjects in need of increasing their bone mass index. In a preferred embodiment, the bone progenitor cells are autologous cells.Compositions and methods for downregulating L1 RNA levels / activity in a subject in need thereof are also provided. The compositions include one or more agents in effective amounts to knockdown L1 RNA in a cell. The compositions can be used to treat conditions associated with ageing. A preferred agent is a L1 RNA antisense oligonucleotide.